Abstract: The present invention provides an intermediate composition enabling to prepare easily and steadily an ?-gel-containing O/W emulsion cosmetic that has a very small viscosity change over time and is excellent in emulsion stability, without using a cooling device that has a heavy burden on cost and the environment, and a production method thereof. An ?-gel intermediate composition consisting of (A) 20 to 80 mass % of a mixture containing one or more higher alcohols having 16 or more carbon atoms and an anionic surfactant in the mole ratio of 3:2 to 5:1, and (B) 20 to 80 mass % of a mixture containing one or more water-soluble solvents having the IOB value of 1.5 to 3.5 and water in the mass ratio of 5:5 to 8:2, and wherein the composition is a liquid consisting of a bicontinuous microemulsion phase or a lamellar liquid crystal-dispersed bicontinuous microemulsion phase at 65 to 85° C. and a solid at room temperature.

Abstract: The invention relates to new compounds of Formula 1: wherein R, R1, are each independently hydrogen, a linear or branched C1-40 alkyl, C2-40-alkenyl or C2-40-alkynyl group, an aryl or C1-40-alkylaryl group; X is H, OH, O(Mn)1/n or R4 where M is a metal ion derived from a lanthanide, actinide, main group or transition metal and V is a substituted C1-40-alkyl, C2-40-alkenyl or C2-40-alkynyl group or an aryl group or C1-40-alkylaryl sulfide, sulfoxide, sulfone, amine or a polyalkyl amine or phosphine or other phosphorous containing group; R4 is a linear or branched C1-40 alkyl, C2-40-alkenyl or C2-40-alkynyl group, an aryl or C1-40-alkylaryl group; e is an integer from 0 to 2; f is an integer from 1 to 100; n is an integer from 1 to 4: the free valences of the silicate oxygen atoms are saturated by one or more of: silicon atoms of other groups of Formula 1, hydrogen, a linear or branched C1-12-alkyl group or by cross-linking bridge members or by polymer chains (R2)2Si(OR3)1O1/2 or (R2)2SiO2/2 or (R2)3SiO1/2

Abstract: The present invention provides a method for treatment of prostatic hyperplasia with banana flower extract. Such banana flower extract can suppress the proliferation of prostate cells and their ability to synthesize dihydrotestosterone. In another aspect, the banana flower extract is also used for ameliorating urinary disturbance. The banana flower extract is a water-soluble extract obtained by sonication and can further be utilized to provide alternatives or supplements for ameliorating symptoms associated with prostatic hyperplasia.

Abstract: The present invention relates to pigments, comprising a plate-like substrate of perlite, and (a) a dielectric material, especially a metal oxide, having a high index of refraction; and/or (a) a metal layer, especially a thin semi-transparent metal layer; a process for their production and their use in paints, ink jet printing, for dyeing textiles, for pigmenting coatings (paints), printing inks, plastics, cosmetics, glazes for ceramics and glass.

Abstract: The present invention relates to a process for the preparation of 17-substituted steroids and, more particularly, to an improved method of preparing micro size abiraterone or derivatives thereof in high yield and purity by means of a spherical agglomeration process.

Abstract: The invention relates to a novel powder, it's method of manufacture and the use thereof in powder material processing, particularly in the manufacture of components formed from compacted powder e.g. discs, monoliths, layers or tablets. The powders comprise coated host particles wherein over 70% of the mass of the powder comprises coated particles smaller than 100 microns. The powders have particular application in the pharmaceutical industry and the technology described can be used to control the properties of active pharmaceutical ingredients. The powders (10) may comprise drug particles (12), carrier particles (14) and additives (16).

Abstract: The invention proposes an antiseptic composition for use as bone cement, in particular an antiseptic polymethylmethacrylate bone cement, that can be cured and comprises a content of at least one component that is a compound with an oxidizing effect or from which a compound with an oxidizing effect can be released. Preferably, hydrogen peroxide is or can be released. In this context, it is particularly preferred to use an adduct or a salt of hydrogen peroxide that releases hydrogen peroxide in the presence of water or aqueous conditions. The antiseptic polymethylmethacrylate bone cement can be used for mechanical fixation of primary total articular endoprostheses, for mechanical fixation of revision total articular endoprostheses, and for producing spacers.

Abstract: Provided is a novel probe for a biological specimen for labelling by itself and clearly visualizing one of a specific cell and a specific cell organ in a living body, the probe having excellent spectral characteristics and exhibiting excellent storage stability. The probe for a biological specimen contains, as an active agent, at least one kind of compound represented by a general formula (I).

Abstract: The invention described herein pertains to the use of oxazolidinone antibiotics, alone or in combination, in the treatment of cancer. In particular, the invention pertains to the treatment of malignant gliomas, thyroid cancer or melanoma, or borderline forms of malignant glioma, thyroid cancer or melanoma.

Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.

Abstract: The invention provides a labeling composition for an intraocular tissue of a living individual, which specifically labels the intraocular tissue without need of an invasive operation such as exposure of an ocular tissue or injection of a staining agent into the ocular tissue or a nerve tissue linking to the ocular tissue, a method of noninvasively labeling an intraocular tissue of a living individual, and a screening method using the labeling composition for the intraocular tissues. The composition contains a compound capable of labeling at least a photoreceptor cell layer of a retina, wherein the compound is a staining compound having a particular structure as a partial structure thereof.

Abstract: A substantially oil- and fat-free single phase, homogenous antioxidant formulation that is readily dispersible in lipid matrices at ambient temperature by gentle stirring. The formulation includes a phenolic antioxidant compound, a liquid carrier, preferably a metal chelator, an emulsifier, and a polarity modifier. In preferred embodiment, a combination of lipid-soluble and water-soluble antioxidant compounds is included to provide an improved antioxidant effect.

Abstract: The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing a single phase solution comprising: (a) a solvent or a mixture of miscible solvents, (b) a liquid carrier material, which is soluble in solvent (a), and (c) a dopant material which is also soluble in solvent (a); (II) cooling (preferably freezing) the single phase solution produced in step (I) to a temperature at which at least both the solvent (a) and carrier material (b) become solid; and (III) removing solid solvent (a) from the cooled (frozen) single phase solution in vapor form, such that the remaining cooled (frozen) carrier material (b) and dopant material (c) are returned to ambient temperature thus providing a product of liquid carrier material (b) having dopant material (c) dispersed therein.

Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.

Abstract: The present invention relates to a drug delivery vehicle comprising a polydiacetylene liposome, wherein a lipid bilayer is formed by a mixture of 10,12-pentacosadiynoic acid (PCDA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and N-palmitoyl homocysteine (PHC), and a drug to be delivered is encapsulated in an isolated inner space of a polydiacetylene liposome. The PDA liposome drug delivery vehicle of the present invention comprises a lipid layer formed by mixing different phospholipids, excluding polydiacetylene, so as to be stable, and thus any leakage problems of an encapsulated drug are eliminated. In addition, since the liposome is sensitive to a pH, the shape and size thereof can be readily changed through the formation of a liposome-liposome conjugate by the improved sensitivity of the drug delivery vehicle under a specific acidic requirement, thereby enabling selective drug release, and thus can be applied as a drug delivery vehicle for various target materials.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a sterile wound dressing having a backing and a nonabsorbent elastomer wound contact layer, wherein the elastomer matrix is formed by a synthetic three-block elastomer, preferably a copolymer of polystyrene block and polyolefin block (SEPS, SEBS, SEEPS, etc.) or mixtures thereof, wherein the total polymer content is less than 3.2 wt %, in particular 3.0 wt % or less, preferably 2.6 wt % or less, and is plasticized by an apolar oil and/or petroleum jelly.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: This invention provides a pre-surgical disinfecting composition that includes at least about 50 percent by weight of a C1-6 alcohol, based upon the total weight of the disinfecting composition, an acid, and a cationic oligomer or polymer. A method for pre-surgical skin disinfection with rapid antiseptic efficacy without the use of secondary antimicrobial compounds is also described.